• Click on Keep in touch with Sanofi and make sure your don’t miss out the latest educational materials for you and your patients.

    A CARDIOLOGIST’S VIEW –Professor Azfar Zaman

    Residual risk in the ACS patient and the contribution of cholesterol
    Post-ACS patients may still be at high risk events despite current statin therapy1. Why is it important to do something differently?

    Why use Praluent in patients with ACS?
    Odyssey Outcomes data demonstrates the benefit of further LDL-C lowering in the post-ACS population2. Why are these results relevant to cardiologists?

    LIPID LOWERING THERAPY: What the core cardiologist needs to know – Dr. Ravi Singh

    Why should we care about lipid lowering, what can we do and how we will do it. A Sanofi sponsored session in a webinar hosted by the BJCA.

    PCSK9-I PATIENT IDENTIFICATION DURING COVID-19 - Dr. Ahai Luvai

    In the following videos Dr. Luvai shares his experience in the identification and management of patients with hyperlipidaemia in the context of the current coronavirus outbreak.

    PCSK9-i initiation during COVID-19:
    Background

    PCSK9-i initiation during COVID-19:
    PCSK9-i education & injection training
    Patient Follow-up

    PCSK9-i initiation during COVID-19:
    PCSK9-I audit North East
    Secondary and Primary care

    References:
    1. Jernberg T, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective European Heart Journal (2015) 36, 1163–1170
    2. Schwartz GG, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018; 379: 2097-2107.